Category: Monkey Pox Vaccine

Page 9«..891011..20..»

Mpox Vaccines May Work Against MPXV Clade I – Precision Vaccinations

December 10, 2023

(Precision Vaccinations News)

The U.S. Centers for Disease Control and Prevention (CDC) today announced aHealth Alert Network (HAN) Health Advisoryabout the occurrence, geographic spread, and sexually associated human-to-human transmission of Clade I Monkeypox virus (MPXV) in the Democratic Republic of the Congo (DRC).

Since January 2023, the DRC has reported 12,569 suspected mpox casesand 581 related deaths from 22 regions.

The new HAN says cases of Clade I MPXV have not been reported in the United States as of December 7, 2023.The global outbreak ofClade II MPXV was initially reported in May 2022.

However, clinicians should be aware of the possibility of Clade I MPXV in travelers who have been in DRC.

Third-party dataindicate that the number of touristsarriving in the DRC wasabout 460,880in 2021.

The CDC recentlyissued aTravel Health Notice (Level 2 - Practice Enhanced Precautions) for people traveling to DRC. Furthermore,there are no direct commercial passenger flights from DRC to the U.S. as of December 2023.

U.S. FDA-approved vaccines (JYNNEOS, ACAM2000) are expected to be effective for both Clade I and II MPXV infections.

Vaccination or prior MPXV infection should provide antibodies that will provide cross-protection to other orthopoxviruses, including Clade I MPXV, says the CDC.

However, clinical verification is under review.

The CDC recommends clinicians encourage vaccination for eligible patients.

Eligible patients who have only received one dose ofBavarian NordicJYNNEOS (MVA-BN, IMVAMUNE) vaccine, which is based on a live, attenuated vaccinia virus,should receive the second dose as soon as possible, regardless of the time that has elapsed since the first dose.

Mpox vaccines have limited availability in the U.S.

Furthermore, clinicians should notify theirstate health departmentif they have a patient withmpox-like symptoms andshouldsubmit lesion specimens for clade-specific testing for these patients.

Continue reading here:

Mpox Vaccines May Work Against MPXV Clade I - Precision Vaccinations

Lethal Strain of Monkeypox Sparks Health Crisis in the DRC – Medriva

December 10, 2023

With the world still grappling with the devastating effects of the COVID-19 pandemic, another health crisis looms. Health officials and experts are increasingly worried about the spread of a lethal strain of monkeypox, particularly in the Democratic Republic of the Congo (DRC). The virus variant, known as Clade I, is more virulent and poses a risk of human-to-human transmission. The World Health Organization (WHO) has expressed grave concerns about the outbreak and its changing epidemiology in the DRC.

The Centers for Disease Control and Prevention (CDC) has issued a health alert regarding this more lethal strain of monkeypox. The outbreak in the DRC has sickened nearly 13,000 people and caused 581 suspected deaths. Cases are believed to be spread via sexual contact, raising fears about its potential for widespread transmission. The situation in the DRC has led to a significant increase in suspected monkeypox cases and deaths, blindsiding health experts globally.

In response to this health crisis, the CDC has instructed clinicians to be vigilant and notify state health departments of any travelers with symptoms similar to monkeypox. The CDC has also emphasized the need for enhanced surveillance and testing in the United States. While there is currently no known risk for Clade I monkeypox in the United States, the CDC is not ruling out the possibility of it emerging in the future.

Countermeasures for Clade II infections, a less severe strain of monkeypox, are expected to be effective against Clade I infections. However, vaccine coverage in the U.S. remains low, with only 1 in 4 eligible people receiving both doses required for full protection. The CDC recommends people at risk for monkeypox to be vaccinated with two doses of the JYNNEOS vaccine, as two doses provide greater protection.

The response to this outbreak is being hampered by stigma, regulatory barriers, and competing disease outbreaks. This lack of urgency in providing vaccines and treatments is reminiscent of the unequal access to vaccines experienced during the COVID-19 pandemic. Concerns about discrimination, particularly in the context of sexual transmission, also add to the complexity of the situation. Despite these challenges, the need for a swift and comprehensive response is imperative.

As the world continues to reel from the impacts of one pandemic, the potential for another is a stark reminder of the interconnectedness of our global health landscape. The situation calls for increased vigilance, improved surveillance, and a renewed emphasis on vaccination. By learning from our experiences with COVID-19 and other infectious diseases, we can hopefully prevent this outbreak from escalating into a global crisis.

Read more here:

Lethal Strain of Monkeypox Sparks Health Crisis in the DRC - Medriva

Health Alert for Monkeypox Virus Outbreak in DRC – CDC Issues Advisory – Medriva

December 10, 2023

The Centers for Disease Control and Prevention (CDC) recently issued a health alert in response to the ongoing outbreak of a more severe and transmissible subtype of the monkeypox (mpox) virus, known as clade I, in the Democratic Republic of Congo (DRC). This alert seeks to prepare clinicians and public health officials in the U.S. for potential cases, despite no clade I cases being reported domestically at this time.

According to the CDC, the 2022-23 global outbreak of mpox was predominantly linked to the clade II monkeypox virus. Interestingly, this outbreak has largely affected gay and bisexual men, as well as other men who have sex with men. However, the clade I subtype, now spreading in the DRC, is raising serious concerns due to its increased transmissibility and severity.

This subtype of the disease has seen a significant surge in its suspected cases and related deaths in the DRC, primarily spreading through sexually associated human-to-human contact.

The CDC has emphasized that the Jynneos mpox vaccine should be effective against both clade I and clade II mpox viruses. However, vaccination coverage in the U.S. remains low. As of now, only one in four people eligible for the vaccine have received the two doses necessary for optimum protection.

Health authorities have recommended travelers to the DRC to be cautious. The CDC advises avoiding close contact with ill or dead animals and promotes enhanced surveillance efforts, especially if the clade I strain is detected in the U.S. Additionally, clinicians are urged to be alert for patients presenting with lesions consistent with mpox.

The World Health Organization (WHO) has expressed great concern over the ongoing outbreak in the DRC, which has proved fatal for nearly 600 people, primarily children, this year. The WHO, in collaboration with Congolese authorities, is currently working on the response and conducting a risk assessment.

Furthermore, CDC and WHO are increasingly concerned about an outbreak among sex workers in South Kivu, DRC. Efforts are being made to work with the Congolese government to procure or accept donations of mpox vaccines.

In light of this health alert, it is crucial that clinicians, public health officials, and individuals who are at risk or are traveling to the DRC remain vigilant. The importance of increasing vaccination coverage against the mpox virus cannot be overstated. By taking these steps, we can help to prevent the spread and severe impacts of this disease.

Read this article:

Health Alert for Monkeypox Virus Outbreak in DRC - CDC Issues Advisory - Medriva

Mpox Outbreak in DRC: Monkeypox Virus Causes Turmoil and Distress – Medriva

December 10, 2023

In the heart of the Democratic Republic of Congo (DRC), a deadly outbreak of a disease known as mpox is causing turmoil and distress. The disease, also known as monkeypox, has claimed many lives, with a reported 12,569 cases and nearly 600 fatalities between 1 January and 12 November 2023. Despite the availability of vaccines and treatments, stigma, regulatory impediments, and the presence of other concurrent disease outbreaks have hindered the response to this growing health crisis.

The ongoing mpox outbreak in the DRC is caused by the monkeypox virus, which is typically transmitted to humans through bites or direct contact with an infected animals blood, body fluids, or cutaneous/mucosal lesions. Interestingly, this outbreak involves a different clade of the mpox virus that reportedly causes more severe disease. For the first time, sexual transmission of this strain is playing a significant role, particularly among men who have sex with men.

The World Health Organization (WHO) has expressed concern about the situation in Congo, warning that the current outbreak presents a significant risk of international spread. The virus spread widely outside of Africa last year, primarily among men who have sex with men. Clade 1 mpox virus, which is currently prevalent in Congo, has a higher fatality rate than the version that spread internationally last year.

Unfortunately, the response to the outbreak has been hindered by several factors. The stigma associated with the disease, particularly due to its sexual transmission, has created barriers to prevention and control. The situation is further complicated by the fact that the DRC is described as hostile to homosexual activities, which could hamper efforts to curb the spread of the disease. Additionally, regulatory hurdles and the governments lack of urgency in responding to the outbreak have been widely criticized. The DRC has not requested to buy or applied for donations of vaccines and treatments, leaving these potentially life-saving resources unused outside the country.

SIGA Technologies, a leading pharmaceutical company, suggests that its antiviral drug TPOXX may be easier to deploy compared to the vaccine. However, this treatment has not yet been approved by the U.S. Food and Drug Administration (FDA), adding another layer of complexity to the situation.

The mpox outbreak in the DRC highlights the global issue of unequal access to vaccines, a concern that has been magnified during the COVID-19 pandemic. The DRCs struggle to utilize available vaccines and treatments underscores the critical importance of addressing these disparities and improving global health infrastructure.

As the mpox outbreak in the DRC continues to unfold, it serves as a stark reminder of the urgent need for global cooperation, accessible healthcare, and the dismantling of stigma and discrimination in the face of health crises. With the right actions and global support, it is hoped that the spread of this deadly disease can be curbed and countless lives saved.

Read the original post:

Mpox Outbreak in DRC: Monkeypox Virus Causes Turmoil and Distress - Medriva

Tonix Pharmaceuticals’ CEO reveals next-generation COVID vaccine technology chosen for key program – Yahoo Finance

November 21, 2023

Vancouver --News Direct-- Tonix Pharmaceuticals

Tonix Pharmaceuticals CEO Dr Seth Lederman recently joined Steve Darling from Proactive to share exciting news about their COVID vaccine, TNX-1800, selected for testing in Project Next Gen, a White House initiative managed by the Department of Health and Human Services, NIH, and NIAID.

The vaccine is based on a live virus platform, providing a unique approach to waking up the immune system. Live virus vaccines, like TNX-1800, offer more durable immunity that lasts a long time and can potentially block virus transmission, addressing limitations seen in mRNA vaccines.

This choice of TNX-1800 is a testament to Tonix's nearly decade-long dedication to vaccine development. The technology platform can also be adapted to protect against other infectious diseases, such as monkeypox, smallpox, and tuberculosis, making it a versatile solution for future pandemics.

This development highlights the significance of vaccine platforms for tackling various infectious threats. Tonix's approach promises to offer more robust, long-lasting immunity and potential transmission prevention, which could revolutionize our approach to infectious disease control. The platform's adaptability positions it as a valuable tool for future vaccine strategies.

Proactive Studio

+1 347-449-0879

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/tonix-pharmaceuticals-ceo-reveals-next-generation-covid-vaccine-technology-chosen-for-key-program-673655021

Original post:

Tonix Pharmaceuticals' CEO reveals next-generation COVID vaccine technology chosen for key program - Yahoo Finance

Yes, adults need vaccines too | Health News | stlamerican.com – St. Louis American

November 21, 2023

Many adults erroneously believe that immunizations are only for kids. However, that is simply not true. There are several vaccines that are recommended in adulthood, some which require more than one.

Many vaccines start in infancy and occur at regular intervals for the first 5 years of life. After childhood, several other immunizations are also recommended. With that being said, vaccine maintenance should be a major component of the yearly physical.

The COVID-19 pandemic should have been an excellent lesson in what can happen when there is widespread infection in our community. It is a known fact that vaccines help prevent disease. Vaccines should be a normal part of any annual wellness exam.

Fall is a great time to review recommended adult vaccines since most providers are discussing the importance of the yearly flu shot anyway. Vaccines help to prevent certain illnesses. They work by introducing your body to an antigen, which pretends to be an illness. Your bodys immune system reacts, and this response will help your body fight certain disease-causing pathogens in the future. So, what are the recommended vaccines for adults?

COVID-19: The COVID-19 virus is constantly changing. If you have been up to date with recommendations thus far, you should be on your 5th COVID-19 vaccine. Per the CDC, vaccination remains the best protection against COVID-19 related hospitalizations and deaths.

HPV: HPV is the human papillomavirus which causes cervical, throat, and anal cancer. The HPV vaccine is recommended as a 2-dose series from ages 9-14 and a 3-dose series from ages 15-45 if you were previously unvaccinated. Unfortunately, only 24.7% of Black people are vaccinated against HPV.

Influenza: The Advisory Committee on Immunization Practices (ACIP) recommends annual influenza vaccines for everyone 6 months and older. It is estimated that from 2019-2020, there were approximately 25,000 deaths and 390,000 hospitalizations related to influenza illnesses.

Mpox (formerly known as monkeypox): Mpox is caused by a virus that is like the virus that causes smallpox. The CDC recommends vaccination against Mpox for certain populations only. For more information, go to CDC.gov.

Pneumococcal: Pneumococcal infections are caused by streptococcus bacteria and can range from ear and sinus infections to serious infections in the blood. The two distinct types of vaccines available protect against many of the pneumococcal bacteria. Pneumococcal vaccination is recommended for all children younger than 5 years old, people 5 through 64 years old who are at increased risk for pneumococcal disease, and adults 65 years and older.

RSV: Recently the FDA approvedthe first of two vaccines for preventing RSV lower respiratory tract disease for adults at least 60 years old. This vaccine is recommended for individuals who are at increased risk. The decision to vaccinate should be discussed with your provider.

Shingrix (Shingles): Adults at least 50 years old should receive 2 doses of Shingrix, separated 2-6 months apart. Adults 19 years old or older with a weakened immune system should also receive 2 doses of Shingrix. Post-herpetic pain (PHN) is a complication of shingles, and the shingles vaccine is the only preventable treatment. Shingrix is more than 90% effective in preventing shingles and PHN.

Tdap: The Tdap vaccine protects against diphtheria, tetanus, and pertussis (whooping cough). Adults should receive the vaccine every 10 years. The vaccine is also important if adults will be around babies.

The COVID-19 pandemic should have been an excellent lesson in what can happen when there is widespread infection in our community. It is a known fact that vaccines help prevent disease. Vaccines should be a normal part of any annual wellness exam. We ALL have a responsibility to maintain the health and wellness of our community. Please do your part and make sure you are up to date on your immunizations!

Denise Hooks-Anderson, MD, FAAFP can be reached atyourhealthmatters@stlamerican.com.

Follow this link:

Yes, adults need vaccines too | Health News | stlamerican.com - St. Louis American

Europe has given up on eliminating monkeypox: It will be just another STD – EL PAS USA

November 21, 2023

At the beginning of this year, the global alarm caused by monkeypox in 2022 had practically vanished. Although the virus was still being closely monitored by public health services, and the World Health Organization (WHO) still considered it a health emergency of international importance (it did not declare the end until May), after 85,000 cases and 89 deaths worldwide, there were three causes for optimism. The first was that the number of new cases had been dropping for months, from the thousand a day reached in August to just a few dozen. The second was its low mortality rate, which was far from the initial forecasts that spoke about 10% of those infected. And finally, the certainty that the virus was inefficiently transmitted outside of the risk behaviors associated with group sexual relations, which ruled out an increase in cases among other population groups.

February was an important moment for decision-making regarding the first global outbreak of monkeypox (which was renamed mpox at the end of 2022). The WHO advocated for a global strategy to control and eliminate the disease, but the European countries had assumed just the opposite: that the virus was here to stay and that trying to get rid of it was not only going to be very difficult, but it would also be too costly and even counterproductive due to the need to apply strict public health measures, which could be met with some social opposition, as was the case at some point of the fight against Covid-19.

This information is revealed by the minutes of the meeting of the Advisory Forum of the European Centre for Disease Prevention and Control (ECDC), held at the organizations headquarters in Stockholm, Sweden, on February 21 and 22 of this year. At the meeting, the Danish representative of the Forum stated that it was important to prepare for long-term work on this issue, because the underlying drivers of the outbreak had not disappeared, and there would be a new young, unvaccinated, sexually active cohort, so there could be a new outbreak. For this reason, complete elimination might not be feasible. By continuing to vaccinate, test and advise the high-risk population, it will be possible to keep the outbreak under control, and monkeypox will be just another sexually transmitted disease. The ECDC Advisory Forum, made up of officials from the organization and the different countries public health guardians, sets the guidelines of the European public health agency.

Mike Catchpole, ECDC chief scientist, added that the cost benefit argument for elimination did not appear to be compelling. This is a reflection of the dilemma that everyone present were facing: continue doing things as before or impose surveillance measures with more or less force, with mandatoriness as a last resort to identify suspected cases, carry out diagnostic tests, comply with quarantines and vaccinate the at-risk population. Measures that should be followed until the virus is eradicated from Europe, and then repeated every time an outbreak caused by an imported case occurs, something that is quite likely considering that the pathogen continues to circulate in other continents such as America and Africa.

The Slovenian representative, on her part, pointed out that as long as monkeypox is perceived as a non-serious disease, it will be very difficult to eliminate, and enforcing these measures will not be an easy task.

As for the vaccines highly sought-after in the early stages of the epidemic the representative of France wondered if there is still interest in them, because HERA (the health emergency preparedness and response department of the EU) had just delivered the second batch of vaccination, but there was little demand for it, unlike last July when there was a shortage. She agreed about not striving for elimination but asked whether countries were confident that they could procure vaccinations, undertake testing and have a long-term strategy for the disease.

The representative of the Netherlands shared the results of the models on the evolution of the disease that were developed in that country, which discourage the adoption of more drastic measures: If the 0.7% of the population who were highly active became infected, a herd immunity threshold was achieved that actually caused the outbreak to wane, as had been observed last summer. Therefore, monkeypox appeared to be less infectious than had been assumed and the highest risk group would have already had the infection, he emphasized.

However, this does not mean that future risks should be ruled out. The outbreak, he said, highlighted the fact that this type of disease could be globally active if introduced into a certain group, and it is important to communicate this fact. The problem, he continued, is that even in a country like the Netherlands, where there is little stigma around this group (men who have relations with multiple same-sex partners), this population segment is hard to reach.

The part of the meeting dedicated to mpox was closed by Vicky Lefevre, head of the Public Health Functions Unit of the ECDC, who stated that the agency would continue to cover ways to reach out and protect this group, in addition to monitoring, testing, raising awareness and offering the vaccination to high-risk groups. As a finishing remark, she mentioned that she was glad to hear that everyone appeared to be in agreement on the elimination issue.

The final stance of the ECDC was made official in a document published two months later describing in detail the recommendations to continue dealing with the mpox outbreak, which do not introduce any major changes to the strategy developed since the summer of 2022. Notably, the word elimination is not mentioned once in the 28 pages of the text.

The meetings of the Advisory Forum are of a technical-scientific nature and all points of view are addressed with the aim of gathering, among all members, the best evidence available for decision-making. In this sense, the Forum would have failed in its functions and its mission if the difficulties involved in any initiative to eliminate a disease and the advisability or not of developing it had not been raised and discussed, states a spokesperson for the Spanish Ministry of Health.

Carlos Maluquer de Motes, professor of molecular virology at the University of Surrey (UK) and expert in smallpox viruses, explains: As a virologist, and taking into account that this virus is similar to that of [traditional] smallpox [already eradicated], I think it is always less risky to opt for a strategy of elimination instead of one of containment, which in the long run gives the pathogen time to continue adapting to humans and reach other population groups.

However, he admits that there are other relevant factors that public health experts take into account in their decision-making. The strategy that eradicated smallpox almost half a century ago included mandatory vaccination, something that is not in line with the current criteria, which are based on voluntary participation and face challenges such as anti-vaccine movements. This requires adapting the response in a way that takes into account the natural immunity of those who have already had the disease, which in this case is favored by the low mortality of mpox. In any case, allowing the virus to continue circulating requires close monitoring and considering measures to adapt the response, if necessary, he continues.

In recent months, there has been a slight increase in mpox cases, something that the WHO and those responsible for public health already feared, given the proliferation of summer festivals in which risky practices are common. According to the latest WHO report, published on October 20 with data from late September, diagnosed cases exceeded 91,000 worldwide, with 157 deaths, most of them in the American continent. In Europe, 229 cases were diagnosed in September, seven times more than in August, although still far from the 2022 figures of several hundred a day.

Sign up for our weekly newsletter to get more English-language news coverage from EL PAS USA Edition

Read more from the original source:

Europe has given up on eliminating monkeypox: It will be just another STD - EL PAS USA

What is monkeypox? – TickerTV News

November 13, 2023

What is monkeypox?

Monkeypox is a rare viral disease that primarily affects animals, including monkeys, rodents, and other mammals. However, it can also be transmitted to humans, causing a similar but less severe illness compared to smallpox. The disease was first identified in 1958 when outbreaks occurred in monkeys kept for research purposes.

The virus responsible for monkeypox belongs to the Orthopoxvirus genus, which also includes the variola virus that causes smallpox. Monkeypox is endemic in Central and West African countries, particularly in remote regions where people have close contact with infected animals.

How is monkeypox transmitted?

Monkeypox can be transmitted to humans through direct contact with infected animals, such as handling their blood, bodily fluids, or lesions. Additionally, human-to-human transmission can occur through respiratory droplets, contact with body fluids, or contaminated objects. The disease is not easily transmitted between humans, and sustained human-to-human transmission is rare.

What are the symptoms of monkeypox?

The symptoms of monkeypox in humans usually appear within 7 to 14 days after exposure to the virus. Initially, individuals may experience fever, headache, muscle aches, and fatigue. This is followed the development of a rash, which typically starts on the face and then spreads to other parts of the body. The rash progresses through different stages, including the formation of fluid-filled blisters that eventually crust over.

Is monkeypox a deadly disease?

Although monkeypox is generally a self-limiting disease, meaning it resolves on its own without specific treatment, severe cases can occur, particularly in individuals with weakened immune systems. In rare instances, monkeypox can be fatal, with a mortality rate of around 1-10%, depending on the strain of the virus.

How can monkeypox be prevented?

Preventing monkeypox primarily involves avoiding contact with infected animals and practicing good hygiene. This includes washing hands regularly with soap and water, avoiding close contact with sick individuals, and using personal protective equipment when handling animals or their specimens.

Is there a vaccine for monkeypox?

Currently, there is no specific antiviral treatment or vaccine available for monkeypox. However, smallpox vaccine has been shown to provide some protection against monkeypox. In case of an outbreak, public health measures such as isolation of infected individuals, contact tracing, and surveillance are implemented to control the spread of the disease.

In conclusion, monkeypox is a rare viral disease that can be transmitted from animals to humans. While it is generally less severe than smallpox, it can still cause significant illness. Preventive measures, such as avoiding contact with infected animals and practicing good hygiene, are crucial in reducing the risk of transmission.

Read more:

What is monkeypox? - TickerTV News

Mpox rising in Oregon, and so is OHA’s warning to act against the virus – KDRV

November 13, 2023

SALEM, Ore. -- Oregon Health Authority is insisting people protect themselves against mpox following an increase in cases of the virus in the state during the past three months.

Oregon Health Authority (OHA) says seventeen mpox cases were reported in about a 100-day span to OHA and local public health authorities between July 20 and October 31.

It is reminding people about the availability of a safe and effective vaccine against mpox, or poxvirus formerly called monkeypox.

OHA says Oregon's recent mpox cases are prompting state health officials to distribute a statewide advisory to healthcare providers this month recommending they consider mpox when evaluating patients with mpox symptoms regardless of the patient's reported risk, vaccination status or level of community transmission. The advisory also states that testing patients with rashes, lesions or symptoms compatible with mpox should be considered part of comprehensive sexual health care.

OHA says mpox spreads primarily through close, skin-to-skin contact, "Most often, it has spread through intimate or sexual contact and during contact with the lesions of an individual with mpox through a caregiving relationship, such as a parent caring for a child or an adult caretaker of another person."

Dr. Tim Menza is senior health adviser for OHAs mpox response who says Oregon recorded one to three mpox cases per month before mid-summer. He says while the recent case increase since July is lower than the 10-15 cases reported weekly at the height of the 2022 outbreak, these cases show mpox is spreading in Oregon, "We never declared the 2022 outbreak over because we were concerned about increases like the one we are seeing now, and it gives us an opportunity to remind folks in the community that vaccination against mpox remains a valuable tool for reducing the risk of mpox infection."

OHA says the JYNNEOS mpox vaccine is free and available to anyone in Oregon who wants to be vaccinated, regardless of insurance status. OHA says, "It is also highly effective: According to a study published in May in the Centers for Disease Control and Preventions (CDC)Morbidity and Mortality Weekly Report, the vaccine was found to be 75% effective for those receiving one dose and 86% effective for those who had two doses."

Mpox symptoms can start between a few days to three weeks after contact, which most commonly are flu-like symptoms of fever, chills, sweats, headache, muscle aches, swollen lymph nodes and fatigue. OHA says most people will develop a rash within a few days of the flu-like symptoms; some people only develop a rash, which may start on or near the penis, testicles, labia, vagina or anus. It may also be on other areas like the hands, feet, chest, face or mouth.

People who suspect they have mpox should contact their healthcare providers to let them know before going in to be seen. The provider may recommend testing for mpox. People who dont have a healthcare provider can call 2-1-1 for help finding a clinic or healthcare provider.

More information about mpox in Oregon is at OHAsmpox websiteor the CDCs mpox page,https://mpoxvaxmap.org/. Vaccination clinics can be searched by ZIP code with the mpox vaccine locator tool athttps://www.oregon.gov/oha/PH/Monkeypox/Pages/vaccine.aspx.

Monkeypox virus

Originally posted here:

Mpox rising in Oregon, and so is OHA's warning to act against the virus - KDRV

These 4 lethal viruses could fuel the next pandemic, new research says. What they areand how the world can prepare – Fortune

November 11, 2023

Deaths from a handful of viruses that spill over from animals to humans are set to increase 12-fold by 2050 due to climate change and habitat encroachment, according to a new study published in the British Medical Journal.

Three of the fourfiloviruses like Ebola and Marburg, SARS, and Nipah virusare on the World Health Organizations list of priority pathogens, noted for their potential to cause the next pandemic.

But the Ebola-like Machupo virus is also a contender, the authors of the new study argue. And regardless of which pathogen ends up fueling the next global health crisis, theyre all worthy of attention, the authors maintain.

The reason: Epidemics of the viruses they focused on are set to cause a combined death toll of more than 15,000 annually by 2050, even if they dont make an evolutionary leap that allows them to ravage the globe.

Researchers at Boston-based biotech firm Ginkgo Bioworks honed in on four viruses likely to pose a significant public health risk and endanger economic or political stability. Called zoonotic viruses, they spill over from animals to humans, who can then transmit them to other humans.

Photo by NurPhoto/NurPhoto via Getty Images

Viruses in this family cause hemorrhagic, or bloody, fevers, which are typically accompanied by bleeding from bodily orifices and/or internal organs. The family consists of five strains of Ebola in addition to Marburgan extremely similar virus that made headlines during an outbreak in Equatorial Guinea earlier this year.

On average, Ebola kills about 50% of those it sickens, though case fatality rates have ranged from 25%-90%, according to the WHO. Marburg also kills around 50% of those it infects, though case fatality rates range from around 24% to 88%, experts say. While there are two licensed vaccines for the deadliest strain of Ebola, Zaire, there arent any for the four other strains. Nor is there an approved vaccine for Marburg, though some are in development.

Photo by JIMIN LAI/AFP via Getty Images

The worlds first confirmed coronavirus pandemic occurred in 2002, when SARS-CoV-1 was reported in China. It spread to more than two dozen countries in North and South America and Europe before being contained seven months later. It is thought to have originated in an animal population, perhaps bats, before being passed to civet catsa tropical animal that looks like a mix of a dog and an ocelotthen to people. A spillover could happen again.

Symptoms include headache, body aches, mild respiratory symptoms, possible diarrhea, an eventual dry cough, and pneumonia in most. SARS sickened nearly 8,100 people and killed just under 10% of them from 2002 to 2003. There is no licensed vaccine for SARS, though researchers are working on universal coronavirus vaccines that could target both SARS and COVID, among other coronaviruses.

C. K Thanseer/DeFodi images via Getty Images

Nipah is a henipavirus, the most lethal of paramyxoviruses. It was first identified in pigs in Malaysia and Singapore in the late 1980s, though its natural reservoir is fruit bats. The other henipavirus known to infect people, Hendra, was first noted in racehorses and humans in Australia in 1994. Both feature respiratory illness and severe flu-like symptoms, and may progress to encephalitisinflammation of the brainalong with other neurologic symptoms and death.

Nipah kills between 45% and 75% of the people it infects. No licensed vaccines exist, though a vaccine by Moderna, in coordination with the U.S. National Institute of Allergy and Infectious Diseases Vaccine Research Center, is being evaluated.

BSIP/UIG Via Getty Images

Also known as black typhus and Bolivian hemorrhagic fever, Machupo was first isolated in Bolivia in 1959. The Calomys callosus field mouse is a natural carrier of the virus, the symptoms of which are Ebola-like and include bleeding, high fever, pain, and rapid death.

Machupo kills between a quarter and a third of those it infects. Though there are no licensed vaccines for it, a vaccine for Argentinean hemorrhagic fevercaused by the similar Junin virusmay also offer protection against Machupo, according to Stanford University.

Researchers only looked at outbreaks that killed 50 or more people between 1963 and 2019. They didnt take into account the following viruses, which may have otherwise met their criteria:

SARS-CoV-2: The virus behind the recent COVID pandemic may have been caused by a lab leak instead of spillover from an animal like a raccoon dog or pangolin. Thus, its not certain that the virus is zoonotic. Whats more, including this disease could skew the studys numbers, making projected deaths look higher than they potentially should be. Regardless, the COVID pandemic occurred just after the studys 2019 cutoff. COVID is, however, on the WHOs list of priority pathogens.

Hantaviruses and Lassa virus: Both rodent-spread viruses were eliminated from consideration because surveillance has increased over time, potentially causing the growth of studied viruses to appear greater than it should be.

Flu and vector-borne pathogens: Flu viruses like 2009s H1N1 and vector-borne diseases like Crimean-Congo haemorrhagic fever and Zika virus were excludedthe former due to surveillance programs that have grown with time, with the potential to skew predictions on the high end, and the latter due to eradication programs that have the potential to skew predictions on the low end.

When crunching numbers on outbreaks, researchers looked at the number of dead, not the number infected. Thats because the number of fatalities is typically more accurate, given that people can contract a disease and show few or no signs of it.

After epidemics were whittled down, the scientists came up with the following calculus:

The figures are likely an underestimate, the authors cautioned.

Most of the 72 outbreaks they examined were caused by filoviruses in Africa like Marburg and Ebola, which comprised more than half of outbreaks. The duo of viruses caused more than 90% of the 17,000-plus total deaths.

While SARS was the No. 2 leading cause of deaths, at 922, it caused a significantly smaller amount of infections, mainly impacting Asiaas did the Machupo and Nipah viruses, which caused 529 deaths combined, mainly impacting South America and Asia.

The researchers findings suggest that spillover events are not an aberration or random cluster, but follow a multi-decade trend in which [such] epidemics have become both larger and more frequent, the authors wrote, adding that urgent action is needed.

One of the most important things we can continue to do is early detection and intervention, which has been shown time and time again through research to be one of the most effective ways to limit the start of an outbreak, Amanda Meadows, a data scientist at Ginkgo and lead author of the paper, told Fortune.

During the pandemic, collective gains were made in wastewater surveillance. COVID is now widely monitored in wastewater, as are other diseases like flu, RSV, and even Mpox (formerly known as monkeypox). An ideal scenario: if pre-existing wastewater surveillance systems are able to screen for potential pandemic pathogens like Ebola, Nipah, and others, giving experts a warning that an outbreak may soon occur, Meadows said.

Even if widespread wastewater surveillance isnt economically feasible, wastewater programs at major international airports like those stood up during the pandemic could alert public health officials to the arrival of such pathogens from overseas, Nita Madhav, senior director of epidemiology and modeling at Ginkgo, told Fortune. Its crucial, she added, that the world maintain the surveillance structure built during COVID for use during future pandemics.

Both Meadows and Madhav said they hope researchers and the public alike dont fall into the classic pandemic panic-neglect cycle that ensures the world is never quite ready for the next global health catastrophe.

Aside from maintaining and even improving on the surveillance network built during the COVID pandemic, Madhav said, theres more that can be done to prevent future pandemics, including small changes made on an individual level.

Pandemics and epidemics are not a foregone conclusion, Madhav said, if we can reduce drivers of risk like climate change, and implications of human interaction with land. Its really powerful that people can make personal choices that directly impact how this plays out over the next decades.

Some actions consumers can take to reduce climate change, according to the United Nations, Natural Resources Defense Council, and Imperial College London:

Read more:

These 4 lethal viruses could fuel the next pandemic, new research says. What they areand how the world can prepare - Fortune

Page 9«..891011..20..»